-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Amarin (NASDAQ:AMRN) Trading 5.8% Higher
Amarin (NASDAQ:AMRN) Trading 5.8% Higher
Amarin Co. plc (NASDAQ:AMRN – Get Rating) shares traded up 5.8% during trading on Tuesday . The stock traded as high as $1.29 and last traded at $1.28. 161,179 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 3,916,424 shares. The stock had previously closed at $1.21.
Analysts Set New Price Targets
Several analysts have commented on the company. The Goldman Sachs Group lowered their price target on Amarin from $1.75 to $1.50 and set a "sell" rating for the company in a report on Tuesday, May 24th. StockNews.com upgraded Amarin from a "sell" rating to a "hold" rating in a report on Wednesday, July 27th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $2.50.
Get Amarin alerts:Amarin Stock Performance
The stock has a market cap of $520.14 million, a PE ratio of -4.86 and a beta of 1.87. The stock has a fifty day simple moving average of $1.44 and a two-hundred day simple moving average of $2.16.
Amarin (NASDAQ:AMRN – Get Rating) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). The company had revenue of $94.44 million during the quarter, compared to analysts' expectations of $88.21 million. Amarin had a negative return on equity of 13.63% and a negative net margin of 21.05%. The firm's revenue was down 38.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.02 EPS. On average, equities analysts predict that Amarin Co. plc will post -0.36 EPS for the current fiscal year.Insider Activity
In other news, Director Olsen Per Wold acquired 55,000 shares of Amarin stock in a transaction that occurred on Monday, June 13th. The shares were purchased at an average cost of $1.69 per share, for a total transaction of $92,950.00. Following the completion of the purchase, the director now directly owns 149,000 shares of the company's stock, valued at approximately $251,810. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.90% of the company's stock.
Institutional Investors Weigh In On Amarin
A number of hedge funds have recently added to or reduced their stakes in AMRN. Creative Planning lifted its stake in Amarin by 66.4% in the second quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 6,900 shares during the last quarter. UMB Bank N A MO bought a new stake in Amarin in the fourth quarter valued at $28,000. Quantbot Technologies LP bought a new stake in Amarin in the first quarter valued at $31,000. Masso Torrence Wealth Management Inc. bought a new stake in Amarin in the fourth quarter valued at $34,000. Finally, Winthrop Advisory Group LLC bought a new stake in Amarin in the first quarter valued at $34,000. 34.15% of the stock is currently owned by institutional investors.
About Amarin
(Get Rating)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Read More
- Get a free copy of the StockNews.com research report on Amarin (AMRN)
- Broadcom Bounces From Institutional Bottom
- Is Autozone A Buy Before Earnings Are Released?
- Affirm is the Underdog Starring in a Spaghetti Western
- Is There Value in Verizon Shares at These Levels?
- MarketBeat Podcast: Stock Market, Bad News is Good News
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
Amarin Co. plc (NASDAQ:AMRN – Get Rating) shares traded up 5.8% during trading on Tuesday . The stock traded as high as $1.29 and last traded at $1.28. 161,179 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 3,916,424 shares. The stock had previously closed at $1.21.
納斯達克的股價在週二的交易中上漲了5.8%。該股一度漲至1.29美元，最後報1.28美元。午盤交易中，161,179股易手，較3916,424股的平均成交量下降了96%。該股此前收盤價為1.21美元。
Analysts Set New Price Targets
分析師設定新的價格目標
Several analysts have commented on the company. The Goldman Sachs Group lowered their price target on Amarin from $1.75 to $1.50 and set a "sell" rating for the company in a report on Tuesday, May 24th. StockNews.com upgraded Amarin from a "sell" rating to a "hold" rating in a report on Wednesday, July 27th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $2.50.
幾位分析師對該公司發表了評論。高盛夫婦在5月24日週二的一份報告中將Amarin的目標價從1.75美元下調至1.5美元，並對該公司設定了“賣出”評級。在7月27日週三的一份報告中，StockNews.com將Amarin的評級從“賣出”上調至“持有”。兩名股票研究分析師對該股的評級為賣出，四名分析師給予該股持有評級，一名分析師給予該股買入評級。根據MarketBeat的數據，該公司的共識評級為持有，共識目標價為2.50美元。
Amarin Stock Performance
Amarin股票表現
The stock has a market cap of $520.14 million, a PE ratio of -4.86 and a beta of 1.87. The stock has a fifty day simple moving average of $1.44 and a two-hundred day simple moving average of $2.16.
該股市值為5.2014億美元，市盈率為-4.86倍，貝塔係數為1.87。該股的50日簡單移動均線為1.44美元，200日簡單移動均線為2.16美元。
Insider Activity
內幕活動
In other news, Director Olsen Per Wold acquired 55,000 shares of Amarin stock in a transaction that occurred on Monday, June 13th. The shares were purchased at an average cost of $1.69 per share, for a total transaction of $92,950.00. Following the completion of the purchase, the director now directly owns 149,000 shares of the company's stock, valued at approximately $251,810. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.90% of the company's stock.
在其他新聞方面，董事奧爾森在6月13日(星期一)的一筆交易中收購了55,000股Amarin股票。這些股票是以每股1.69美元的平均成本購買的，總交易額為92,950.00美元。收購完成後，董事現在直接擁有14.9萬股該公司股票，價值約251,810美元。這筆交易是在提交給美國證券交易委員會(Securities&Exchange Commission)的一份文件中披露的，可以通過這個超級鏈接訪問。公司內部人士持有該公司0.90%的股份。
Institutional Investors Weigh In On Amarin
機構投資者看好Amarin
A number of hedge funds have recently added to or reduced their stakes in AMRN. Creative Planning lifted its stake in Amarin by 66.4% in the second quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 6,900 shares during the last quarter. UMB Bank N A MO bought a new stake in Amarin in the fourth quarter valued at $28,000. Quantbot Technologies LP bought a new stake in Amarin in the first quarter valued at $31,000. Masso Torrence Wealth Management Inc. bought a new stake in Amarin in the fourth quarter valued at $34,000. Finally, Winthrop Advisory Group LLC bought a new stake in Amarin in the first quarter valued at $34,000. 34.15% of the stock is currently owned by institutional investors.
一些對衝基金最近增持或減持了amrn的股份。創意策劃在第二季度增持了66.4%的Amarin股份。Creative Planning現在擁有這家生物製藥公司17,285股股票，價值26,000美元，上個季度又購買了6,900股。UMB Bank N A MO在第四季度購買了Amarin的新股份，價值2.8萬美元。Quantbot Technologies LP在第一季度購買了Amarin的新股份，價值3.1萬美元。馬索·託倫斯財富管理公司去年第四季度以3.4萬美元的價格購入了Amarin的新股份。最後，Winthrop Consulting Group LLC在第一季度購買了Amarin的新股份，價值3.4萬美元。34.15%的股票目前由機構投資者持有。
About Amarin
關於阿瑪林
(Get Rating)
(獲取評級)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Amarin Corporation plc是一家制藥公司，在美國、德國、加拿大、黎巴嫩和阿拉伯聯合酋長國從事心血管疾病治療藥物的開發和商業化。它的主要產品是Vascepa，一種僅限處方的omega-3脂肪酸產品，用作飲食的輔助產品，用於降低患有嚴重高甘油三酯血癥的成年患者的甘油三酯水平。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Amarin (AMRN)
- Broadcom Bounces From Institutional Bottom
- Is Autozone A Buy Before Earnings Are Released?
- Affirm is the Underdog Starring in a Spaghetti Western
- Is There Value in Verizon Shares at These Levels?
- MarketBeat Podcast: Stock Market, Bad News is Good News
- 免費獲取StockNews.com關於Amarin的研究報告(Amrn)
- 博通從機構底部反彈
- AutoZone是在收益發布之前買入的嗎？
- 阿奎姆是意大利西部片中的失敗者
- 在這些水平上，Verizon的股價有價值嗎？
- 市場Beat播客：股市，壞消息就是好消息
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿馬林日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Amarin和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧